Emerging Therapeutic Options for Higher-Risk Melanoma

The discussion focuses on high-risk melanoma, particularly stage 2B, 2C, and lymph node-involved cases, emphasizing emerging therapeutic options. Local therapy often involves excision and sentinel lymph node biopsy (SLNB), which is indicated for tumors with a higher risk of micrometastatic disease. Current trials like the Mellmark aim to explore optimal clinical margins. Landmark studies like MSOT demonstrated the prognostic value of SLNB, albeit controversial regarding immediate lymph node dissection's benefit, leading to a shift toward ultrasound surveillance for positive lymph nodes. Notably, systemic therapies have gained prominence in managing melanoma, with immunotherapy and targeted therapy dramatically changing the treatment landscape. Emerging trials support the use of adjuvant therapies for stage 2B and 2C patients, with recent studies like Keynote 716 showing significant risk reductions with pembrolizumab. A notable development is the exploration of neoadjuvant approaches, where early systemic therapy precedes surgery, potentially enhancing outcomes and allowing surgical de-escalation based on pathologic responses. This evolving framework indicates a need for better prognostic markers and further research into individualized treatment regimens, as many patients do not respond to existing therapies. The conclusion emphasizes the importance of SLNB, the promising role of neoadjuvant strategies, and the ongoing need for innovative therapies.